Fintel reports that on May 14, 2024, RBC Capital initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Outperform recommendation.
Analyst Price Forecast Suggests 4.05% Upside
As of May 8, 2024, the average one-year price target for Perspective Therapeutics is 1.81. The forecasts range from a low of 1.52 to a high of $2.52. The average price target represents an increase of 4.05% from its latest reported closing price of 1.74.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Perspective Therapeutics is 11MM, an increase of 657.11%. The projected annual non-GAAP EPS is -0.13.
What is the Fund Sentiment?
There are 83 funds or institutions reporting positions in Perspective Therapeutics. This is an increase of 20 owner(s) or 31.75% in the last quarter. Average portfolio weight of all funds dedicated to CATX is 0.23%, an increase of 675.53%. Total shares owned by institutions increased in the last three months by 83.15% to 64,299K shares.
What are Other Shareholders Doing?
Hills Bank & Trust holds 10,358K shares representing 1.76% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,673K shares representing 1.65% ownership of the company. No change in the last quarter.
Baker Bros. Advisors holds 7,640K shares representing 1.30% ownership of the company. No change in the last quarter.
Geode Capital Management holds 4,376K shares representing 0.75% ownership of the company. In its prior filing, the firm reported owning 2,517K shares , representing an increase of 42.49%. The firm increased its portfolio allocation in CATX by 355.02% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 3,105K shares representing 0.53% ownership of the company. No change in the last quarter.
Perspective Therapeutics Background Information
(This description is provided by the company.)
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
